Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX)

A number of firms have modified their ratings and price targets on shares of Gain Therapeutics (NASDAQ: GANX) recently:

• 12/22/2025 – Gain Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Gain Therapeutics had its “buy” rating reaffirmed by analysts at Roth Capital. They now have a $10.00 price target on the stock.
• 12/19/2025 – Gain Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
• 12/10/2025 – Gain Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Gain Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Gain Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.